DR. KENNETH R FEINGOLD, MD
Osteopathic Medicine at Forbes Ave, San Rafael, CA
License number
California G36300
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
214 Forbes Ave, San Rafael, CA 94901
Phone
(415) 221-4810
(415) 750-2005
(415) 750-6927 (Fax)
(415) 750-2005
(415) 750-6927 (Fax)
Professional information
Treatment Of Skin Conditions By Use Of Ppar Activators
US Patent:
RE37770, Jun 25, 2002
Filed:
Jan 8, 2001
Appl. No.:
09/756828
Inventors:
Peter M. Elias - Mill Valley CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Assignee:
The Regents of the University of California - Oaklland CA
International Classification:
A61K 3120
US Classification:
514560, 514256, 514543
Abstract:
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor , and oxysterol activators of the LXR receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
Treatment Of Skin Conditions By Use Of Ppar.alpha. Activators
US Patent:
6060515, May 9, 2000
Filed:
Jun 16, 1999
Appl. No.:
9/101366
Inventors:
Peter M. Elias - Mill Valley CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 3120
US Classification:
514560
Abstract:
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor. alpha. , and oxysterol activators of the LXR. alpha. receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
Treatment Of Skin Conditions With Oxysterol Activators Of Lxr.alpha.
US Patent:
6184215, Feb 6, 2001
Filed:
Aug 24, 1999
Appl. No.:
9/382031
Inventors:
Peter M. Elias - Mill Valley CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 3156
US Classification:
514182
Abstract:
Disorders of the skin and mucous membranes that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor. alpha. , and oxysterol activators of the LXR. alpha. receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
Activators And Ligands Of Ppar-Beta/Delta For The Treatment Of Skin Conditions
US Patent:
2003007, Apr 24, 2003
Filed:
Apr 12, 2002
Appl. No.:
10/121954
Inventors:
Peter Elias - Mill Valley CA, US
Kenneth Feingold - San Rafael CA, US
Matthias Schmuth - San Francisco CA, US
Kenneth Feingold - San Rafael CA, US
Matthias Schmuth - San Francisco CA, US
Assignee:
The Regents of the University of California, a California Corporation - Oakland CA
International Classification:
A61K031/426, A61K031/421, A61K009/00
US Classification:
424/400000, 514/365000, 514/374000
Abstract:
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier, disturbed differentiation, or inflammation are treated or prevented by topical application of compounds that are activators of peroxisome proliferator-activated receptor-delta.
Neutralization Of Stratum Corneum To Treat Hyperkeratotic Skin Lesions
US Patent:
2003011, Jun 19, 2003
Filed:
Dec 14, 2001
Appl. No.:
10/017841
Inventors:
Peter Elias - Mill Valley CA, US
Kenneth Feingold - San Rafael CA, US
Joachim Fluhr - San Francisco CA, US
Theodora Mauro - San Francisco CA, US
Martin Behne - San Francisco CA, US
Kenneth Feingold - San Rafael CA, US
Joachim Fluhr - San Francisco CA, US
Theodora Mauro - San Francisco CA, US
Martin Behne - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K031/4965
US Classification:
424/401000, 514/255060
Abstract:
Hyperkeratotic skin lesions are treated by the topical administration of inhibitors of hydrogen ion pumps, transporters, and antiporters, or buffers with a pH of 7.0 or greater, and inhibitors of physiological processes that generate free fatty acids from complex lipids.
Treatment Of Skin Conditions With Fxr Activators
US Patent:
6187814, Feb 13, 2001
Filed:
Oct 29, 1999
Appl. No.:
9/429070
Inventors:
Peter M. Elias - Mill Valley CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Nathan N. Bass - San Francisco CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31215
US Classification:
514531
Abstract:
Disorders of the skin and mucous membranes that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor. alpha. , and oxysterol activators of the LXR. alpha. receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
Lipids For Epidermal Moisturization And Repair Of Barrier Function
US Patent:
5643899, Jul 1, 1997
Filed:
Feb 27, 1995
Appl. No.:
8/347363
Inventors:
Peter M. Elias - Muir Beach CA
Kenneth R. Feingold - San Rafael CA
Carl R. Thornfeldt - Ontario OR
Kenneth R. Feingold - San Rafael CA
Carl R. Thornfeldt - Ontario OR
Assignee:
Cellegy Pharmaceuticals, Inc. - Foster City CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
A61K 3159, A61K 3123, A61K 3120, A61K 3116
US Classification:
514171
Abstract:
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of a formulation comprising certain of the three major epidermal lipid species or their structurally similar precursors, isomers, or analogs in certain proportion ranges. This invention utilizes the following lipid species in unique combinations of two or more components: cholesterol, an acylceramide, a ceramide, and essential and nonessential fatty acids. These combinations are effective both as moisturizing agents and agents for the restoration of barrier function. Some of these combinations are further enhanced by the addition of known moisturizers such as petrolatum and glycerine.
Fxr, Ppara And Lxra Activators To Treat Acne/Acneiform Conditions
US Patent:
6071955, Jun 6, 2000
Filed:
Feb 25, 1999
Appl. No.:
9/257356
Inventors:
Peter M. Elias - Mill Valley CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Karen Hanley - Mill Valley CA
Kenneth R. Feingold - San Rafael CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31335
US Classification:
514475
Abstract:
Acne vulgaris and acneiform skin conditions are treated by the application of compounds that is juvenile hormone III, 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid methyl ester.
Therapeutic Sepsis Treatment Using Antagonists To Pthrp
US Patent:
5660826, Aug 26, 1997
Filed:
Jun 6, 1995
Appl. No.:
8/477348
Inventors:
Carl Grunfield - San Francisco CA
Janet Funk - San Francisco CA
Kenneth R. Feingold - San Rafael CA
Janet Funk - San Francisco CA
Kenneth R. Feingold - San Rafael CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39395
US Classification:
4241451
Abstract:
Methods and compositions are provided for the treatment or prophylaxis of systematic inflammatory response syndrome by administering an antagonist to parathyroid hormone-related protein, such as antibodies to PTHrP.
Skin Barrier Function And Cohesion Through Enhanced Stratum Corneum Acidification
US Patent:
2003011, Jun 19, 2003
Filed:
Dec 14, 2001
Appl. No.:
10/017038
Inventors:
Peter Elias - Mill Valley CA, US
Kenneth Feingold - San Rafael CA, US
Joachim Fluhr - San Francisco CA, US
Theodora Mauro - San Francisco CA, US
Martin Behne - San Francisco CA, US
Kenneth Feingold - San Rafael CA, US
Joachim Fluhr - San Francisco CA, US
Theodora Mauro - San Francisco CA, US
Martin Behne - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K038/46, A61K031/685, A61K031/66
US Classification:
424/094600, 514/114000, 514/078000
Abstract:
The integrity, barrier function, cohesion and antimicrobial defense of the stratum corneum pH are improved by acidification, which is achieved by the application of low pH buffers, enzymes, phospholipids or salts with monovalent cations.